Carboprost Tromethamine Market Size was valued at USD 1.6 Billion in 2023. The carboprost tromethamine market industry is projected to grow from USD 1.7 Billion in 2024 to USD 2.09 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.40% during the forecast period (2024 - 2032). The main market driver propelling the expansion of the carboprost tromethamine market is the increase in the incidence of postpartum hemorrhage.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
One of the leading causes of maternal mortality in the world is postpartum hemorrhage or excessive postpartum hemorrhage. The use of drugs such as carboprost tromethamine to control and reduce postpartum hemorrhage is increasingly important due to the increasing incidence of PPH. One consequence of high birth rates is also the high incidence of postpartum hemorrhage. The BMC Journal of Reproductive Health published an article in March 2022 stating that one of the leading causes of maternal mortality in developing countries is perinatal mortality, which accounts for approximately 25.0-43.0% of all maternal deaths. We also talked about how it stood out. This rise in postpartum hemorrhage has boosted sales of therapeutic and injectable carboprost tromethamine. The global market CAGR of carboprost tromethamine will grow rapidly during the forecast period owing to high fertility and the increasing prevalence of postpartum hemorrhage (PPH).
The awareness of obstetric care and pertinent actions to avoid maternal morbidity and death has grown dramatically as a result of advancements in healthcare infrastructure and advances in obstetric care. Global healthcare systems are progressively implementing emergency services and standard operating procedures with the aim of improving maternal health outcomes. The inclusion of carboprost tromethamine in these procedures is indicative of its established effectiveness in lowering blood loss and averting PPH-related maternal morbidity and mortality. Healthcare professionals are also taught how to use carboprost tromethamine correctly. This guarantees that they can safely and effectively deliver the drug in emergencies, hence improving the results for mothers. Consequently, during the projection period, healthcare systems will support the expansion and development of the market as long as they maintain their current level of quality and draw in new investments to upgrade their infrastructure. Thus, driving the carboprost tromethamine market revenue.
The Carboprost Tromethamine Market segmentation, based on application, includes Pregnancy Abortion and Postpartum Hemorrhage Treatment. In 2023, the postpartum hemorrhage treatment segment dominated the market, driven by the global rise in pregnancies, the frequency of postpartum hemorrhage, and the number of deliveries. Postpartum hemorrhage is the primary cause of maternal death worldwide. For instance, the World Health Organization estimates that 14 million women worldwide suffer from PPH, which leads to over 70,000 maternal fatalities annually. In addition, the women who survive are permanently disabled from reproducing and require surgical procedures to stop the bleeding. Products containing carboprost tromethamine thereby assist women during labor, lowering the rate of maternal death.
The Carboprost Tromethamine Market segmentation, based on distribution channel, includes Hospital Pharmacies, Drug Stores, and Others. The hospital pharmacies category generated the most income in 2023. The industry is predicted to rise as a result of medications becoming more widely available at hospital pharmacies. Hospital pharmacists now have more chances to support patients with risk prevention techniques, PPH patient emergency management, pharmacotherapy assessment, sterile product preparation, and medication mistake avoidance.
Figure 1: Carboprost Tromethamine Market, by Distribution Channel, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American carboprost tromethamine market area will dominate this market ascribed to the region's expanding need for carboprost tromethamine due to the increased incidence of postpartum hemorrhage, rising pregnancy rate, rising number of childbirths, rising number of unintended pregnancies, and rising abortion rate. Furthermore, pharmaceutical research and innovation are concentrated in North America, which promotes improvements in treatment techniques and drug development.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: CARBOPROST TROMETHAMINE MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe carboprost tromethamine market accounts for the second-largest market share. The region offers a sophisticated healthcare infrastructure, including cutting-edge hospitals, clinics, and pharmacies that can handle obstetric crises. Additionally, it is anticipated that the region's market for carboprost tromethamine will grow as a result of increased research and development in clinical-stage firms for novel treatments for postpartum hemorrhage. Further, the German carboprost tromethamine market held the largest market share, and the UK carboprost tromethamine market was the fastest growing market in the European region.
The Asia-Pacific Carboprost Tromethamine Market is expected to grow at the fastest CAGR from 2024 to 2032 since governments and hospitals around Asia are taking significant chances to improve maternal healthcare and reduce the number of maternal deaths. Initiatives to successfully handle postpartum hemorrhage are noteworthy because they are influencing market change and driving demand for drugs like carboprost tromethamine. Moreover, China’s carboprost tromethamine market held the largest market share, and the Indian carboprost tromethamine market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the carboprost tromethamine market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, carboprost tromethamine industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global carboprost tromethamine industry to benefit clients and increase the market sector. In recent years, the carboprost tromethamine industry has offered some of the most significant advantages to medicine. Major players in the carboprost tromethamine market are attempting to increase market demand by investing in research and development operations, including Hikma Pharmaceuticals PLC, Pharmacia and Upjohn Company LLC (a division of Pfizer Inc.), Sandoz Inc. (a Novartis Division), LGM Pharma, Pfizer Inc., JHP Pharmaceuticals, LLC, Sun Pharmaceutical Industries Ltd, among others.
Sandoz Inc. (Sandoz), a generic pharmaceutical firm, is a subsidiary of Sandoz Group AG. It develops, produces, distributes, and markets a variety of prescription medications as well as protein and biosimilars globally. Active pharmaceutical ingredients (APIs) and biotechnology production services are among the intermediary products that the company offers to other businesses. It offers completed dosage forms and active ingredients for medications in the fields of gastrointestinal, hormone treatments, pain management, ophthalmology, central nervous system, cancer, cardiovascular, respiratory, and metabolism.
Branded generics and generic medicines are only a few of the pharmaceutical formulations that Sun Pharmaceutical Industries Ltd. (Sun Pharma) provides. Products for treating neurological, psychiatric, gastroenterological, orthopedic, ophthalmologic, and cardiac illnesses are among the company's offerings. The business creates complicated formulations, active pharmaceutical ingredients (APIs), and over-the-counter medications in addition to doing process chemistry and product development. The medication is available in different dose forms, including tablets, inhalers, capsules, injectables, creams, ointments, and liquids.
Key companies in the carboprost tromethamine market include
May 2023: The US Food and Drug Administration has officially approved Eugia Pharma Specialties, a wholly-owned subsidiary of Aurobindo Pharma, to manufacture and market injectable carboprost tromethamine.
February 2022: Amneal Pharmaceuticals LLP states that the Food and Drug Administration (FDA) has approved carboprost tromethamine injection. Utilization in second-trimester abortion cases and for terminating pregnancies between 13 and 20 weeks of gestation—as indicated by the first day of the most recent normal menstrual cycle—is recommended.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 1.6 Billion |
| Market Size 2024 | USD 1.7 Billion |
| Market Size 2032 | USD 2.09 Billion |
| Compound Annual Growth Rate (CAGR) | 3.40% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Application, Distribution Channel, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Hikma Pharmaceuticals PLC, Pharmacia and Upjohn Company LLC (a division of Pfizer Inc.), Sandoz Inc. (a Novartis Division), LGM Pharma, Pfizer Inc., JHP Pharmaceuticals, LLC, Sun Pharmaceutical Industries Ltd, among others. |
| Key Market Opportunities | · Increasing publicly funded family planning services |
| Key Market Dynamics | · Increased incidence of postpartum hemorrhages · Growing government and non-governmental organization efforts |
Frequently Asked Questions (FAQ) :
The Carboprost Tromethamine Market size was valued at USD 1.6 Billion in 2023.
The global market is projected to grow at a CAGR of 3.40% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are Hikma Pharmaceuticals PLC, Pharmacia and Upjohn Company LLC (a division of Pfizer Inc.), Sandoz Inc. (a Novartis Division), LGM Pharma, Pfizer Inc., JHP Pharmaceuticals, LLC, Sun Pharmaceutical Industries Ltd, among others.
The postpartum hemorrhage treatment category dominated the market in 2023.
The hospital pharmacies category had the largest share in the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
